51results about How to "Poor outcome" patented technology

A wireless fetal and maternal monitoring system includes a fetal sensor unit adapted to receive signals indicative of a fetal heartbeat, the sensor optionally utilizing a Doppler ultrasound sensor. A short-range transmission unit sends the signals indicative of fetal heartbeat to a gateway unit, either directly or via an auxiliary communications unit, in which case the electrical coupling between the short-range transmission unit and the auxiliary communications unit is via a wired connection. The system includes a contraction actuator actuatable upon a maternal uterine contraction, which optionally is a EMG sensor. A gateway device provides for data visualization and data securitization. The gateway device provides for remote transmission of information through a data communication network. A server adapted to receive the information from the gateway device serves to store and process the data, and an interface system to permits remote patient monitoring.

An apparatus for treatment of soft tissue includes a source of radiation, a handpiece which is adapted to transmit radiation emitted from the source of radiation to a region of soft tissue, resulting in irradiated soft tissue, said handpiece being positioned adjacent to or in contact with said soft tissue region, a grid element adapted to hold at least one temperature sensor in contact with or embedded in said region of soft tissue, and a microprocessor, which converts a signal from the at least one temperature sensor into a measure of damage produced in at least two components of the irradiated soft tissue, said components comprising at least one normal tissue component and at least one malignant, hypertrophic, diseased, or unwanted component.

A modified release solid dosage product comprises a plurality of minicapsules or minispheres containing nimodipine, wherein when exposed to a use environment more than 40% of the nimodipine is released within 12 hours and wherein the Tmax is reached within 6 hours. The product may be a capsule 4 having a first population of uncoated minispheres 1 containing nimodipine for immediate release and a second population of coated minispheres 2 containing nimodipine for sustained release. There may be another population of coated minicapsules 3.

A system, workflow and facilities for hybrid tissue banks are provided with a central access way having spaces on both sides for public and private diagnostic areas, public and private clean room areas for processing, culturing and other manufacturing steps, public and private storage areas, wherein air flow is into said clean rooms and out of said diagnostic areas and said storage areas, and wherein all public facilities are on one side of the central access-way and private facilities are on the other side, and wherein there are sample pass-throughs between each area, and at least the sample pass-through into and out of the clean room processing areas comprise small enclosed chambers having two access panels (one leading to each space), wherein only one panel can open at a time. Preferably, these areas are preceded by receiving spaces and terminated by shipping spaces, which also have pass-through chambers.

Systems and methods recited herein provide for affixation of a prosthetic valve to surrounding tissue, by at least one anchor and an anchor deployment device. The prosthetic valve device may be compliant with native tissue and may receive the at least one anchor in at least one anchor receptacle to affix the prosthetic valve to native tissue. The anchor may include a distal tip, a proximal head, and a tension component, such that upon deployment into tissue the tension component is situated in a tensioned state to exert a pulling force on the distal end of the anchor.

A method for distinguishing between kidney dysfunctions in a mammal, including pre-renal azotemia, an acute renal injury that may progress to acute renal failure, and chronic kidney disease, using a urinary or circulating NGAL assay result that is compared to a predetermined NGAL cutoff level, and a single serum or plasma creatinine measurement. Typically the single creatinine measurement cannot distinguish acute renal injury from chronic kidney disease or pre-renal azotemia, a single measurement of urinary NGAL, combined with the single serum or plasma creatinine measurement, has sufficient sensitivity and specificity to distinguish acute renal injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes. Patients admitted to the emergency department of the hospital with any of acute kidney injury, prerenal azotemia, chronic kidney disease, or even normal kidney function, can be evaluated based on the single measurements of urinary or circulating NGAL, and serum or plasma creatinine. Urinary NGAL level is highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit.

The invention provides methods for determining the prognosis of a patient diagnosed with a leukemia, including B-cell chronic lymphocytic leukemia, by measuring mutations of the WT1 gene in a biological sample. The invention also relates to the diagnosis of leukemia, including B-cell chronic lymphocytic leukemia.

An apparatus for treatment of soft tissue includes a source of radiation, a handpiece which is adapted to transmit radiation emitted from the source of radiation to a region of soft tissue, resulting in irradiated soft tissue, said handpiece being positioned adjacent to or in contact with said soft tissue region, a grid element adapted to hold at least one temperature sensor in contact with or embedded in said region of soft tissue, and a microprocessor, which converts a signal from the at least one temperature sensor into a measure of damage produced in at least two components of the irradiated soft tissue, said components comprising at least one normal tissue component and at least one malignant, hypertrophic, diseased, or unwanted component.

A method of treatment of mild to moderate non-penetrating closed traumatic brain injury and mild to moderate TBI due to surgical intervention using 3-hydroxybutyate glycerides is disclosed.

This document provides methods and materials for modulating afferent nerve signals to treat medical conditions such as CHF, CHF respiration, dyspnea, peripheral vascular disease (e.g., peripheral arterial disease or venous insufficiency), hypertension (e.g., age-associated hypertension, resistant hypertension, or chronic refractory hypertension), COPD, sleep apnea, and chronic forms of lung disease where muscle dysfunction is a part of the disease pathophysiology. For example, methods and materials involved in using electrical and / or chemical techniques to block or reduce afferent nerve signals (e.g., nerve signals of group III and / or IV afferents coming from skeletal muscle and / or the kidneys) are provided.

The invention belongs to the technical field of the immunology, and relates to a detection kit for the severe septicopyemia and the acute liver failure. The detection kit comprises a sodium citrate contained anticoagulant tube, an erythrocyte lysate, a PBS solution, a CD45 human monoclonal antibody, a CD14 human monoclonal antibody, a CD16 human monoclonal antibody, and a 1% paraformaldehyde fixing solution. The detection kit can detect the peripheral bloods of septicopyemia and acute / acute-on-chronic liver failure patients through detecting the monocyte differentiation capability in order to determine the prognosis of the above diseases. Detection results show that the obstacles of the monocyte differentiation capability of the diseases still exist; and the peripheral blood monocyte differentiation repression is closely related with the disease prognosis because the mortality of monocyte differentiation repression patients obviously increases and the monocyte differentiation repression patients can survive after the disappearance of the differentiation repression. The detection kit provides positive meaningful reference data for further treatment schemes.

A short wave infrared (SWIR) imaging system and method of using the same is provided for assessing a tissue damage depth and / or readiness for reconstruction and / or debridement. The SWIR imaging system includes a light source for illuminating the wound or burn, an image light-registering camera system having at least one narrow-band SWIR filter to image the wound or burn and output imaging information, and a detection system for receiving the imaging information and processing the imaging information to determine a tissue damage depth and / or readiness for reconstruction and / or debridement assessment.